COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis (BLXA4)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02342691
Recruitment Status : Unknown
Verified December 2017 by The Forsyth Institute.
Recruitment status was:  Active, not recruiting
First Posted : January 21, 2015
Last Update Posted : December 12, 2017
National Institute of Dental and Craniofacial Research (NIDCR)
Information provided by (Responsible Party):
The Forsyth Institute

Brief Summary:

The primary objective is to evaluate the safety of an investigational compound, BLXA4-ME, topically applied as a daily oral rinse in adults with gingivitis. Safety will be assessed by the incidence of adverse events, including mucosal inflammation and irritancy and findings from safety labs. Subjects will be monitored for development of periodontitis, and oral flora will be analyzed to detect an increase in opportunistic organisms.

The secondary objective is to assess preliminary efficacy of the oral rinse, by monitoring changes in the plaque index (PI), modified gingival index (MGI), bleeding on probing (BOP) and levels of interleukin -1β (IL-1β) in gingival crevicular fluid (GCF).

The study comprises three groups in a randomized, placebo-controlled double-blind clinical trial design. The treatment group (1.0 μM BLXA4-ME oral rinse) and the placebo rinse group will each include 50 subjects. The no-rinse control group will consist of 25 subjects. Subjects in the treatment and placebo rinse groups will receive oral rinse (BLXA4-ME or placebo) to be applied once daily after morning teeth brushing. Safety parameters will be assessed before and after 3, 7, 14, 21, and 28 days of treatment. Efficacy parameters will be assessed before and after 14 and 28 days of treatment.

Condition or disease Intervention/treatment Phase
Gingival Inflammation Drug: BLXA4 Drug: Placebo oral rinse Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 125 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 / 2 Clinical Trial to Assess the Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis
Study Start Date : September 2016
Actual Primary Completion Date : September 28, 2017
Estimated Study Completion Date : December 2018

Arm Intervention/treatment
Experimental: BLXA4-ME oral rinse
The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
Drug: BLXA4
BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.

Placebo Comparator: Placebo oral rinse
The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
Drug: Placebo oral rinse
The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste

No Intervention: No Rinse Control
The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients

Primary Outcome Measures :
  1. incidence of adverse events [ Time Frame: up to 90 days ]
    Adverse events will be recorded throughout the study, and may include events reported by subjects or changes observed in oral cavity examinations or vital signs (assessed at baseline, Days 3, 7, 14, 21 and 28). Blood and urine will be collected for safety labs at Days 14 and 28 after product administration, and subjects will undergo close monitoring for mucosal inflammation and irritancy and development of periodontitis, using standard clinical periodontal measurements. Follow-up will also occur at 90 days to assess for adverse events.

Secondary Outcome Measures :
  1. Supragingival Plaque [ Time Frame: 28 days ]
    Plaque will be measured using the Silness and Loe Plaque Index [Silness and Loe 1964]

  2. Gingival Inflammation [ Time Frame: 28 days ]
    Gingivitis will be measured using the Modified Gingival Index [Gordon et al 1985]

  3. Gingival Bleeding [ Time Frame: 28 days ]
    Gingival Bleeding will be assessed using the dichotomous bleeding on probing index

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Signed consent form
  • Good general health as evidenced by medical history
  • Age 18 - 65
  • Must have a stable address and be available for the duration of the study
  • Must have a minimum of 20 natural teeth, excluding third molars
  • Must have a mean full mouth MGI of at least 2.0
  • Must be willing to use prescribed oral hygiene procedures and products
  • Medications for chronic conditions must be stable for at least 3 months prior to enrollment
  • Women of reproductive potential must use licensed hormonal contraception or double barrier methods
  • Men of reproductive potential must agree to use condoms
  • Liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, and total bilirubin) levels equal to or less than 1.5 times the upper limit of normal
  • Serum creatinine levels equal to or less than the upper limit of normal;
  • Subjects with complete blood count levels within 10% of the normal laboratory range and erythrocyte sedimentation rate equal to or less than 2 times the upper limit of normal.

Exclusion Criteria:

  • Presence of orthodontic appliances or removable partial dentures
  • Presence of a soft tissue tumor of the oral cavity
  • Presence of gross plaque or calculus (≥ 75% of tooth surfaces)
  • Presence of extensive restorations that could affect the marginal gingiva (at the investigators' discretion)
  • Preexisting oral pathology, including carious lesions requiring immediate treatment or ulcerations of the mucosa
  • Current participation in another clinical trial or product test
  • Pregnant or breast feeding
  • Residence in the same household as a subject currently enrolled in the study (due to potential blinding and compliance issues)
  • Concomitant endodontic therapy or periodontal therapy other than prophylaxis within the past 6 months
  • History of early onset periodontitis or acute necrotizing ulcerative gingivitis
  • Chronic disease with concomitant oral manifestations, such as autoimmune or immunosuppressive diseases (e.g., human immunodeficiency virus, severe combined immunodeficiency, neutropenia, juvenile arthritis, systemic lupus erythematosus, sickle cell anemia, Crohn's disease, rheumatoid arthritis, Sjögren's syndrome) or immunocompromised status due to cancer chemotherapy, hematopoietic stem cell or solid organ transplant, head and neck radiotherapy, splenectomy, chronic steroid usage
  • Recent history of chronic alcohol consumption of more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer, or five 5 ounce servings of wine per day
  • Tobacco use (former tobacco users may be enrolled, provided they have been tobacco-free for one year or more)
  • Diabetes mellitus
  • Subjects with urinalysis results suggestive of infection (if a subject meets this criterion, he/she may be rescreened for study participation when he/she no longer meets this exclusion criterion)
  • Medical conditions that the investigator considers significant and that may interfere with the examination or the safety of the subject
  • Chronic use (2 weeks or more) of medication known to affect periodontal status within one month of enrollment (such as ≥81mg aspirin, phenytoin, calcium antagonists such as nifedipine, NSAIDs, coumarin, cyclosporine, ≥10 mg/day atorvastatin or equivalent dose of another statin [Subramanian et al, 2013]);
  • Treatment with antibiotics within one month prior to enrollment
  • Medical condition for which antibiotic treatment during the study period is likely or a condition for which antibiotic prophylaxis is recommended before dental procedures (American Heart Association guidelines of 2007 will be followed)
  • Known hypersensitivity to any component of the test or placebo products
  • Anything that, in the opinion of the investigator, would place the subject at increased risk or prevent the subject from fully complying with or completing the study -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02342691

Layout table for location information
United States, Massachusetts
The Forsyth Institute
Cambridge, Massachusetts, United States, 02142
Sponsors and Collaborators
The Forsyth Institute
National Institute of Dental and Craniofacial Research (NIDCR)
Layout table for additonal information
Responsible Party: The Forsyth Institute Identifier: NCT02342691    
Other Study ID Numbers: 16-085-E
U01DE026934-01 ( U.S. NIH Grant/Contract )
First Posted: January 21, 2015    Key Record Dates
Last Update Posted: December 12, 2017
Last Verified: December 2017
Keywords provided by The Forsyth Institute:
Safety and efficacy of BLXA4
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Gingival Diseases
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases